5.2.2.5 α-reductase inhibitors. mechanism action: androgen effects prostate mediated dihydrotestosterone (dht), converted testosterone enzyme 5α-reductase , two isoforms: 5α-reductase type 1: predominant expression activity skin liver.5α-reductase type 2: predominant expression activity prostate. two 5-aris available clinical use: dutasteride finasteride. finasteride inhibits 5α-reductase type 2, whereas dutasteride inhibits 5α-reductase types (dual 5-ari). 5-aris induce apoptosis prostate epithelial cells leading prostate size reduction 18-28% decrease circulating psa levels 50% six twelve months treatment . mean prostate volume psa reduction may even pronounced long-term treatment. continuous treatment reduces serum dht concentration approximately 70% finasteride 95% dutasteride. however, prostate dht concentration reduced similar level (85-90%) 5-aris. efficacy: clinical effects relative placebo seen treatment least six months. two four years treatment 5-aris improve ipss approximately 15-30%, decrease prostate volume 18-28%, increase qmax 1.5-2.0 ml/s patients luts due prostate enlargement [65,163,164,181-187]. indirect comparison one direct comparative trial (twelve months duration) indicated dutasteride finasteride equally effective treatment luts . symptom reduction depends initial prostate size. finasteride may efficacious placebo patients prostates < 40 ml . however, dutasteride seems reduce ipss, prostate volume, risk aur, increase qmax even patients prostate volumes 30 40 ml . long-term trial dutasteride symptomatic men prostate volumes > 30 ml increased risk disease progression showed dutasteride reduced luts least much α1-blocker tamsulosin . greater baseline prostate volume (or serum psa level), faster pronounced symptomatic benefit dutasteride compared tamsulosin. 5α-reductase inhibitors, α1-blockers, reduce long-term (> 1 year) risk aur need surgery . pless study, finasteride reduced relative risk aur 57% need surgery 55% (absolute risk reduction 4% 7%, respectively) four years, compared placebo . mtops study, finasteride reduced relative risk aur 68% need surgery 64% (absolute risk reduction 2% 3%, respectively), also four years . pooled analysis three rcts two-year follow-up data, reported treatment finasteride decreased relative risk aur 57%, surgical intervention 34% (absolute risk reduction 2% both) patients moderately symptomatic luts . dutasteride also demonstrated efficacy reducing risks aur bpo-related surgery. open-label trials demonstrated relevant changes urodynamic parameters . furthermore, finasteride might reduce blood loss transurethral prostate surgery, probably due effects prostatic vascularisation, although evidence clinically significant effect mixed [197-199]. tolerability safety: common adverse events reduced libido, erectile dysfunction (ed) less frequently, ejaculation disorders retrograde ejaculation, ejaculation failure, decreased semen volume . gynaecomastia (with breast nipple tenderness) develops 1-2% patients. two studies suggested treatment 5-aris associated higher incidence high-grade cancers although causal relationship proven . long-standing debate regarding potential cardiovascular side effects 5-aris, particular dutasteride . population-based studies taiwan ontario find association use 5-aris increased cardiovascular side effects . british-taiwanese population-based cohort study, risk type ii diabetes higher men 5-aris men receiving tamsulosin differ dutasteride finasteride . large swedish cohort study showed increased risk depression finasteride (hr 1.61) dutasteride (hr 1.68), long-term association dementia suicide risk . practical considerations: treatment 5-aris considered men moderate-to-severe luts enlarged prostate (> 40 ml) and/or elevated psa concentration (> 1.4-1.6 ng/ml). prevent risk aur need surgery. due slow onset action, suitable short-term use. effect psa needs considered relation pca screening. summary evidenceleafter two four years treatment, 5-aris improve ipss approximately 15-30%, decrease prostate volume 18-28%, increase qmax 1.5-2.0 ml/s patients luts due prostate enlargement.1b5α-reductase inhibitors prevent disease progression regard aur need surgery. due 5-aris slow onset action, suitable long-term treatment (years).1athe relevant adverse effects 5-aris related sexual function, include reduced libido, ed less frequently, ejaculation disorders retrograde ejaculation, ejaculation failure, decreased semen volume well breast enlargement breast tenderness.1b recommendationsstrength ratinguse 5α-reductase inhibitors (5-aris) men moderate-to-severe luts increased risk disease progression (e.g., prostate volume > 40 ml).strongcounsel patients slow onset action 5-aris.strong